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RECOMENDACIONES PARA EL SOPORTE 
NUTRICIONAL Y METABÓLICO ESPECIALIZADO
DEL PACIENTE CRÍTICO. ACTUALIZACIÓN. 
CONSENSO SEMICYUC-SENPE: PACIENTE 
ONCOHEMATOLÓGICO
Resumen
Los pacientes portadores de cáncer, en cualquier fase
de su evolución, pueden precisar ingreso en UCI como
consecuencia de complicaciones secundarias a su enfer-
medad de base o de las terapias quirúrgicas o farmacoló-
gicas a que se ven sometidos para tratar su enfermedad.
La propia enfermedad cancerosa, así como el estado crí-
tico a que pueden derivar como consecuencia de las com-
plicaciones sobreañadidas, con frecuencia condicionan
un alto grado de hipermetabolismo y de déficit de ingesta
nutricional, lo que conduce en estos enfermos a una alta
incidencia de desnutrición. Además, la propia enferme-
dad cancerosa condiciona una utilización anómala de los
sustratos nutritivos, lo que podría condicionar una vía de
administración y una proporción y aporte de nutrientes
algo diferenciado de los pacientes no tumorales.
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Abstract
Patients with cancer, irrespective of the stage of their
disease, can require admission to the intensive care unit
as a result of the complications of their underlying
process or the surgical or pharmacological treatment
provided. The cancer itself, as well as the critical status
that can result from the complications of the disease, fre-
quently lead to a high degree of hypermetabolism and
inadequate energy intake, causing a high incidence of
malnutrition in these patients. Moreover, cancer causes
anomalous use of nutritional substrates and therefore the
route of administration and proportion and intake of
nutrients may differ in these patients from those in non-
cancer patients.
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Introduction
Cancer patients with solid tumors may enter the
intensive care unit (ICU) as a result of certain surgical
treatments, applying in these cases the same recom-
mendations as with any surgical patients in ICU.
Patients undergoing hematopoietic stem cell transplan-
tation may require admission to ICU for severe compli-
cations of the treatment itself: graft versus host disease,
hepatic venoocclusive disease, infectious complica-
tions, and mucositis.
Malnutrition affects a high number of the patients
with solid tumors, and can occur throughout the course
of the disease1. Cachexia is present in over two thirds of
patients dying of advanced cancer and may be the direct
cause of a fourth of deaths2. The etiopathogenesis of
cachexia includes anorexia and metabolic changes asso-
ciated with neoplastic disease. Anorexia is the conse-
quence of hypophagia, mucositis, gastric repletion, nau-
sea, diarrhea, constipation, mechanical obstruction, and
malabsorption. The metabolic changes are mediated by
proinflammatory cytokines that cause changes in energy
expenditure and metabolism of macronutrients.
In cancer, resting energy expenditure (REE) may be
normal, increased, or decreased. The type of tumor and
its phase will play a major role in this behaviour1. In
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turn, the metabolism of macronutrients is impaired in
patients with neoplasic disease, which leads to an
anaerobic metabolism of glucose, and glycolysis is an
ineffective energy production method, which involves
that the tumor takes large amounts of glucose at a high
metabolic cost. With regards to lipids there is an
increase in lipolysis over lipogenesis3,4. In addition,
tumours produce factors, such as the lipid mobilizing
factor, that induce degradation of the adipose tissue
with production of fatty acids.
Finally, there is a progressive reduction of the skele-
tal muscle mass, with relatively preserved visceral pro-
tein mass and increased liver protein mass (synthesis of
acute phase proteins). Low plasma concentrations of
insulin (or its resistance) and the action of different
mediators (cytokines, neuropeptides) activate proteo -
lytic pathways.
Are there any specific issues to assess 
the nutritional state of these patients?
Although nutritional assessment does not require
special considerations, specific methods have been
vali dated for cancer patients. Patient-Generated Sub-
jective Global Assessment (PG-SGA) is a procedure
combining data on objective and subjective issues
derived from the clinical history and from the physical
examination5. Although this is the procedure of choice,
as it has been shown that it may predict prognosis6,7
(III), it is not always possible to do it at the ICU,
because it requires that the patient completes a number
of data. However, the subjective global assessment
performed by experts is the most reliable malnutrition
parameter on admission and represents the recom-
mended tool for critically-ill patients.
What are the energy and protein needs 
of critically-ill cancer patients?
Several authors have described an increased of REE
in cancer patients8 (III), 9 (Ib), while others have found
no changes from healthy controls10 (III). Evidence
suggests that REE is variable based on the type of
tumor, disease activity and presence of complications11
(IIb). In critically-ill oncohematological patients an
REE increase of about 20% is estimated in patients
with solid tumors,1 exceeding 10% in hematopoietic
stem cell transplant patients12. Protein needs are also
increased, without differences from those of any criti-
cally-ill patient13 (III).
Does the cancer disease condition the 
administration route of specialized 
nutritional support?
There are no studies that show a better response of
antitumor therapy, with chemotherapy and/or radiation
therapy, on supplementing it with parenteral nutrition
(PN) if there is no serious dysfunction of the intestinal
route. In contrast, most studies show a higher rate of
infectious complications and poorer prognosis when
tumor patients are nourished with PN14 (Ia), 15 (Ib).
The study of Bozzetti et al.15 (Ib) reported that
patients with gastrointestinal tumors, undergoing
surgery, have fewer complications if they are adminis-
tered nutritional support immediately after surgery.
This improvement was more evident in previously
malnourished patients and in those nourished enterally.
Another study, upon comparing the postoperative com-
plications in patients operated for colorectal cancer
nourished by enteral versus parenteral route, reported a
lower complication rate in the group nourished by
enteral route16 (Ib).
Mucositis can make digestive intake difficult due to
the difficulties on placement of naso or orogastric
tubes, which may involve the use of pharyngostomies
or gastrostomies, or even the use of PN. Furthermore,
in patients with hematological tumors, the develop-
ment of thrombocytopenia may be a relative con-
traindication due to the bleeding risk. Some prelimi-
nary studies suggest that in these cases performing a
prophylactic ostomy could reduce the development of
malnutrition17 (III), but there are currently no conclu-
sive studies analyzing in critically-ill patients the
advantages of these ostomies or PN over approach with
nasogastric tubes.
Do oncological/hematological patients require 
specific modifications in the enteral or parenteral
nutrition formulae? 
Lipid supply
Of the studies available in cancer patients, some of
them are contradictory in relation to glucose intole -
rance18 and others support normal or increased lipid
oxidation3,4 (IV). Thus, some authors suggest that these
patients should be recommended to increase lipid supply
in PN at values above 35% of energy requirements.
Eicosaepentanoic acid
The anti-inflammatory and antitumor effects of
eicosaepentanoic acid (EPA) seen in recent years have
led to introducing these nutrients as part of the treat-
ment of cancer patients. However, the studies attempt-
ing to demonstrate the efficacy of nutritional support
including use of EPA show contradictory results.
Although prolonging survival after oral supplemen -
ting with EPA vs placebo could not be reproduced, and
even contrary outcomes have been obtained19, other
studies have reported improved outcomes in several
clinical parameters. On the one hand, the review per-
formed by the Cochrane in 2007 concluded that there
51
11. CHAPTER 11 .qxd:02. SINDROME.qxd  22/11/11  9:26  Página 51
are insufficient data to establish that oral supplements
with EPA are superior to placebo, both alone and in
combination with high protein supplements, to
improve symptoms associated with cachexia20. On the
other hand, in a systematic review also in 2007, Elia et
al.21 observed a decrease of complications, particularly
infectious, as well as a shortening of hospital stay and
improved nutritional parameters in patients on enteral
nutrition (EN) supplemented with EPA, but concluded
that further research is needed to confirm this. Colomer
et al.22, in a systematic review, found benefits in diffe -
rent clinical, biochemical, and functional parameters
when administering EPA supplements in diet or as cap-
sules for at least 8 weeks in certain types and situations
of cancer. These findings have not been confirmed in
critically-ill cancer patients.
Glutamine
The beneficial results obtained by some authors in
patients undergoing autologous transplant of hemato -
poietic stem cells on supplementing EN with gluta-
mine, with reduced severity and duration of mucositis23
(Ib), could not be confirmed by other authors24,25. PN
with glutamine, at doses of 0.5 g/kg/day, may have
beneficial effects by reducing local harmful intestinal
effects (atrophy) and the liver damage caused by
chemotherapy and radiation therapy26 (Ib). In addition,
improvements have been reported in nitrogen balance,
in immune function, risk of infection, hospital lengh of
stay and healthcare costs27,28 (Ib). Effects on mortality
have been contradictory29,30 (IIa). In addition, in a ran-
domized, double-blinded study in autologous bone
marrow transplantation, high doses of glutamine
dipeptide involved a greater number of relapses, mor-
tality and costs31.
Water, electrolytes, vitamins, trace elements 
and fiber
No information is available which allows for giving
special recommendations on water, vitamins, elec-
trolytes, trace elements and fiber in these patients.
Recommendations
– Patient-generated subjective global assessment is
the technique of choice for nutritional status assess-
ment, as it has been shown that it can predict the prog-
nosis of these patients (B).
– Calorie-protein supply in critically-ill oncohema-
tological patients must be similar to that in other criti-
cally-ill patients (B).
– In previously malnourished patients with gas-
trointestinal tumors who undergo surgery it is recom-
mended to administer nutritional support immediately
after surgery (A).
– Cancer patients may benefit from parenteral nutri-
tion formulae, with lipid supplies > 35% of total calorie
supply (C).
– No adequate data are available to support the use,
enteral or parenteral, of w-3 fatty acids supplements in
patients with advanced cancer (C).
– In patients undergoing autologous hematopoietic
stem cell transplantation, supplementing enteral nutri-
tion with glutamine decreases severity and duration of
mucositis (C).
– It is recommended to supplement parenteral nutri-
tion with alanyl-glutamine at doses of 0.5 g/kg/day in
bone marrow transplant patients (A).
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